Old Wegmaster from Yahoo Board
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Coincidence, NEO announcement 2 days before Amgen exit effective date....?
Did you see this post earlier? G Brown
Interesting UPENN’s Dr Mason continues to push ahead with her own work utilizing HER2 to treat canine osteosarcoma. She announced a planned 80 dog trial in June 2017 coordinated with NCI and sponsored via a $1M grant from Morris Animal Foundation. She stressed at the time of the announcement a parallel goal of promoting HER2 to treat juvenile osteosarcoma since the disease is indistinguishable in dogs and children.
Reading between the lines she obviously feels HER2 is an Lm medical construct worthy of development. It’s also interesting her continuing efforts with HER2 and expanded canine trials seem to compete with PETX AT-014 efforts.
In addition to UPENN, who is conducting part of the 80 dog trials, they’ve enlisted partner schools to assist with the trials as reflected in the attached links. Tufts and K-State are reflected as recruitment sites. There may be others I didn’t find in researching the initiative.
https://www.vet.k-state.edu/vhc/services/clinical-trials/ListeriaVaccineCanineOsteosarcoma.html
https://trials.vet.tufts.edu/clinical_trials/a-vaccine-therapy-for-treatment-of-dogs-with-osteosarcoma-bone-cancer/
I can’t imagine the patience required or the frustration endured by researchers like Dr. Mason who’s original breakthrough work with HER2 that doubled, and in some cases more than tripled, life expectancy of dogs diagnosed with osteosarcoma is now 6-7 years old. Her original sample was small. Her 80 canine initiative is likely her effort to prove a point.
Agenus stock was where ADXS is in November, now 3.5. Not a big uptick for such a great deal. Ditto for ADXS, please.[color=red][/color]
RS is insurance/ reserve/ backup plan for the plan we want executed. Partner! Hot getting moving.
Canine news....something to get us over a buck. D day on reverse split would be months. Summer?
Bristol Meyers story today. We have to be in the right place. Impact on ADXS?
(Bloomberg) -- Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo didn’t sell as well as analysts had expected in the fourth quarter, suggesting that the drugmaker is facing increasing pressure in a competitive market for immunotherapy treatments.
Opdivo sales were $1.80 billion in the quarter, falling short of Wall Street’s average estimate of $1.84 billion. The company also withdrew an FDA application for another use of Opdivo in lung cancer, a key immuno-oncology field.
Key Insights
Bristol-Myers’s growth has been dependent on the performance of its top seller, which accounts for almost 30 percent of sales. While Opdivo has been approved to treat several forms of cancer, it’s lost some market share to Merck & Co.’s rival medication Keytruda. Much of Bristol-Myers’ 10 percent sales growth in the quarter came from Opdivo and the anticoagulant Eliquis. Its older drugs, which it calls “Established Brands,” declined across the board.The company’s reliance on just a handful of top-selling therapies is one reason that this month it bid $74 billion for Celgene Corp. Celgene has made a multitude of bets on experimental therapies, and has several blockbuster products of its own.
We sure could use that 2 mill in the ADXS bank account.
16 days until Amgen termination date. As bad as that is, ADXS is a free agent to do something with ADX NEO with a big partner who was not a monster deadbeat. Amgen walked away after putting a lot of money in. Thank you very much in a weird way.
"Pursuant to the terms of the Amgen Agreement, upon Amgen's termination, the license to Amgen will terminate and the Company will regain worldwide rights for the development and commercialization of its ADXS-NEO program. In addition, Amgen will have certain obligations as set forth in the Amgen Agreement, including promptly deleting or destroying any materials related to the development or manufacturing of the ADXS-NEO program"
Read more at:
https://thefly.com/landingPageNews.php?id=2837062
By the way is this concept highly unusual of the custom treatment with neoantigens...? I hope a winner.
ADXS-NEO creates a customized treatment with neoantigens specifically selected based on a biopsy of the patient’s tumor.
I agree, the money from canine does not mean as much as the PR and validation. It was the first and I hope can be the first to truly capture the world's attention, not to mention save so many dogs. I always wonder about all that Purina food.... and why so much canine cancer. I heard 1 out 2 dogs get cancer before 10.
One more discussion item. Can Hot provide shorter term results?
"Received U.S. Food and Drug Administration allowance of the Investigational New Drug application for the Company’s first ADXS-HOT off-the-shelf neoantigen drug candidate, ADXS-503, for the treatment of all types of non-small cell lung cancer;"
I would like to see some news within 2 months on some data or partners. This company should be a stock that we bought years ago, forgot about for many years and then cashed in after steady appreciation as a long term play. Yet we have been manipulated by greedy mgt and day trading short investment. I am just hoping science will prevail over all of it.
Sorry Shub, I remember you from Yahoo, I was Wegmaster. I am going for the long ride...they did spend way too much cash. I can only pray for a partner and cash coming in. And to get above a buck.
2 questions, why would they want a reverse split? Who bought the 6 mill shares?
Re: Regarding NEO and HOT and had additional meetings on those programs and have had discussions on AXEL and cervical cancer as well, and we are having some discussions with folks and have generated some term sheets are relating to partnering both the prostate cancer as well as the AXEL asset.
Any value to above?
Have you tried? Will you try and get a question in?
So any guesses who bought the 6 million shares? (or 5 mill plus)
Trading question: What is the actual mechanism that allows 6 mill shares to trade on open market in one day. One Tute places an order to sell 5 mill and another Tute buys them? Do they plan on it in advance, if true? Ethical/ legal? Shares bought throughout the day. Or is just investors like us? ;)
I appreciate the understanding.
5 million shares and up .20 Something is cooking. I am trying to smell the bacon.
James, Hov, would their be a requirement or strategy that IF a new partner was in the works to have to wait to Feb 8 (Amgen exit date) to announce?
Held, I hope you held and did not bail. That is an uplifting story and I would like a Ditto. I am wondering that IF something is cooking that ADXS would have reason to wait to announce til Feb 8 when Amgen is officially out?[color=red][/color]
No is getting my shares either, I remained buckled in for the ride. I am convinced that we have been picked on during long waiting periods of uncertainty...biotech conundrum. Insiders could be hedging (i.e. those who have large shares as compensation and own restricted shares) No doubt Amgen has comppeting/ conflicting interests, but they have been silent for a long time. I sense a real player partner coming soon....(and pray/ hope) The science does not have one negative except the long time period it takes. All this guessing that someone knows something we don't is BS.
I did hear Martha Stewart bought a 200,000 shares ;)
I am not an expert in schedules, but I do know that in this industry they can be long and painfully slow. Our FDA....which is partially shutdown.
Dawson, On the Medford case. At the 2:00 minute mark in the video, it says they have used on 8 cases and ALL have been successful.
Rain rain go away.
come again another day.
Advaxis is the only way.
Its the real deal. Patient stories are incredible and real.
https://www.advaxis.com/patient-stories/
Survivor Story: Recovery from Head and Neck Cancer with axalimogene filolisbac and surgery
Mt. Sinai was 8 for 8!
Europe shuts down completely during this time period...."Lazy Americans" are the ones who work the most holidays. ;)
I thought same, but not actually over until effective date 2/8?
Silence. I keep wondering why we don't see some BS PR to try and settle down the panic. I have an optimistic guess that they are not showing there cards for reasons. What are the reasons, 2/9 requirement? New Deal with someone like Merck? Tech breakthrough they don't want to reveal until Amgen formally over? It is peculiar to not have any comments at all.
Market Cap 12.9 mill, cash almost 50 mill, less now, but I bet over 40 mill. I like your Merck pick, a bargain for them now.
Recent SEC rules I heard require such folks to reveal offsetting hedges with puts and short positions. I wonder how much of that has happened with our CEOs etc.
Many have told you there has been NO bad news on science. You are guessing.
I agree. This appears bad, but it could remove handcuffs of Amgen. We only know the bad side right now. If true, the stock is a steal of a buy right now. I keep wondering hoping there is agenda to this we don't know about. Staying secret til Feb 8 could be painful.
I am feeling the same pain. I am not that religious, but praying a bad thing with Amgen, becomes a good thing for new opportunities. Trying to keep faith and praying for survival, especially for the good of beating cancer with LM Tech. I can't wait to get bashed for this by all the bitter Bobs.
Let's say they had a deal with someone else in the wings, must they wait til 2/8 to announce?
"Bad" results aren't coming out yet, no matter what people think. All this guessing by Sour Grape people. Without an undercover investigation, no-one knows. ADXS is a struggling free agent, but there is no scientific bad news on record.
Wow, that is long overdue. I believe an officer with restricted shares can hold puts and never disclose publicly in the past....
One more guess, could Amgen have been due for a milestone payment and was dragging its feet, would not pay and Advaxis actually pushed them for money due and they walked.
Amgen basically gave ADXS $75- 80 mill and got nothing back....ADXS owns all and is free to do what it wants. But no future Amgen money is the big loss....if I understand correctly?
Dew, I don't think the market knows science. While cash is the issue, ADXS has stayed its course with pipeline all and all.
Why Friday Feb 8, any significance of the date?
But does ADXS want partner.... and how do they pay for it? What don't we know....PR is horrible
Advaxis said it will be evaluating whether or not to find a new developmental partner for the ADX-NEO program.
Management Commentary June 18
“Everything we are striving to accomplish depends on focus and optimal allocation of resources, and is designed to maximize shareholder value. We are dedicating more resources to the HOT program because these assets scored very high when we conducted our portfolio review,” said Mr. Berlin. “This program, along with our NEO program which is partnered with Amgen, hold great potential in the exciting and fast-developing field of neoantigens and have application across multiple tumor types in high-value indications. Therefore, it is important for us to allocate increased resources to realize the potential of these programs and to allow for more rapid advancement in this competitive field.”
Advaxis has also decided to increase internal investment in the ADXS-NEO and ADXS-HOT programs, both of which target neoantigens, a potentially transformational, next-generation approach to treating cancer.
Both the ADXS-NEO and the ADXS-HOT programs aim to instruct T cells to selectively attack neoantigens and, in the case of ADXS-HOT, against other tumor-associated antigens, with the goal of controlling tumor growth and prolonging life. Advaxis’ proprietary Lm platform uniquely positions the company in the development of advanced T cell therapeutics compared with other approaches. This belief is based on, among other things, data derived from more than 530 patients treated with AXAL and other product candidates, showing a manageable safety profile, induction of immune responses and clinical activity.
Amgen has made zero milestone payments over many years. They have not been active in any way. Great name, big pharm, but did nothing for ADXS. I can only pray that ADXS is now free to make a better deal with another big pharm. Perhaps someone wanted Amgen out before they came in....sound good? Grasping for straws at this point.